SRPT Sarepta Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · Ver en SEC EDGAR ↗ cerrar Oct 2, 2026 10-K/10-Q Ago 5, 2026SRPT Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
SRPT Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
La granularidad de las barras se adapta al período seleccionado; pase el ratón sobre el gráfico para ver la apertura/máximo/mínimo/cierre de una barra.
| Fecha ex-dividendo | División | Tipo |
|---|---|---|
| 12 de julio de 2012 | 1-for-6 | Inversa |
Acerca de Sarepta Therapeutics, Inc. - Common Stock Descripción general de la empresa de Wikipedia
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.
History
Sarepta started in Corvallis, Oregon on January 1, 1980 and was originally named Antivirals Inc. After occupying several research laboratory spaces in Corvallis, the company opened a production laboratory in Corvallis in February 2002 and was renamed AVI BioPharma Inc. The company made headlines in 2003 when it announced work on treatments for severe acute respiratory syndrome (SARS) and the West Nile virus. In July 2009, the company announced they would move their headquarters from Portland, Oregon, north to Bothell, Washington, near Seattle. At that time, the company led by president and CEO Leslie Hudson had 83 employees and quarterly revenues of $3.2 million. AVI had yet to turn a profit and had not yet developed any commercial products as of July 2009. The company lost $19.7 million in the second quarter of 2009, and then won an $11.5 million contract with the U.S. Department of Defense's Defense Threat Reduction Agency in October 2009. By this time, the company had completed its headquarters move to Bothell.
In 2012, the company moved a second time, to Cambridge, Massachusetts. At the time, CEO Chris Garabedian indicated the move was motivated by the need to recruit expertise in rare diseases. The Corvallis laboratory facility was closed in 2016.
In June 2017, Sarepta Therapeutics appointed former Allergan executive Doug Ingram as its new CEO to replace Edward Kaye who had announced plans to step down earlier that year.
In February 2019, Sarepta acquired five gene therapy candidates for $165 million after one of them, MYO-101, produced results with a new gene therapy candidate for patients with Limb-Girdle muscular dystrophy; two months after receiving a single treatment, muscles from all three patients were producing the protein they couldn't make on their own. In 2019, the FDA rejected a Serepta Duchenne muscular dystrophy drug before reversing course 3 months later.
The company opened a new Genetic Therapies Center of Excellence in Columbus, Ohio in October, 2021 in order to dramatically advance research into therapeutics for several muscular dystrophies that had begun at Nationwide Children's Hospital several years earlier. As of 2022, there are three FDA-approved DMD drugs in Sarepta Therapeutics' portfolio. In January 2023, Sarepta partnered with Catalent to manufacture delandistrogene moxeparvovec (SRP-9001).
In June 2023, the FDA approved Sarepta Therapeutics’ fourth therapy, delandistrogene moxeparvovec-rokl, the first gene therapy to treat Duchenne muscular dystrophy (DMD). The product was approved under the accelerated approval pathway for 4-5 year olds with a confirmed DMD diagnosis. Accelerated approval requires that the product be studied further to verify its clinical benefit.
In July 2025, Sarepta announced plans to lay off 500 employees, about 36% of its workforce, following the deaths of two patients linked to its Duchenne muscular dystrophy gene therapy, ELEVIDYS. The layoffs are part of a restructuring effort expected to generate around $400 million in cost savings by 2026.
Products
Its primary products are based on Morpholino oligomers (PMOs), synthetic nucleic acid analogs that were conceived of by James Summerton and invented by Summerton with Dwight Weller, originally developed under the name NeuGene Antisense. Since morpholino oligomers can form sequence-specific double-stranded complexes with RNA they are suitable use in antisense therapy. In one application, translation blocking, a morpholino oligomer binds to messenger RNA produced by a known disease-causing gene to prevent it from being translated into protein. Morpholinos can also work as splice-switching oligos, targeting pre-mRNA to alter splicing and so causing changes in the structure of the mature mRNA (the mechanism of the approved drug eteplirsen). Morpholinos have been tested for a wide range of applications including prevention of cardiac restenosis after angioplasty, treatment of coronary artery bypass grafts, treatment of polycystic kidney disease, redirection of drug metabolism, treatment of some mutations causing Duchenne muscular dystrophy (DMD), and inhibition of infectious diseases. Their greatest clinical and commercial success thus far has been in the treatment of DMD. A new class of Morpholino oligos, the peptide-linked Morpholinos or PPMO, are linked to an arginine-rich cell-penetrating peptide to enhance their delivery into cells and have entered clinical trials.
The Morpholino drug eteplirsen, targeting exon 51 of the dystrophin mRNA, was approved as a human therapeutic by the FDA in 2016 and antisense oligonucleotides for Morpholinos targeting other exons are also subsequently approved. Morpholinos have been used in preclinical studies to inhibit replication of a broad range of viruses, including influenza, West Nile virus, SARS, hepatitis C, dengue fever, Ebola and Calicivirus, all of which are single stranded RNA viruses. They are in advanced development for prevention and treatment of Ebola and Marburg viruses. In March 2013, the Company announced positive results from a non-human primate study of AVI-7288, the drug candidate for treatment of Marburg virus infection. The results showed that intramuscular administration of AVI-7288 resulted in survival rates up to 100 percent in monkeys exposed to this fatal virus. These results are similar to those in previous studies when the drug was given by intravenous injection.
In December 2019, golodirsen (Vyondys 53) received US FDA approval for the treatment of cases that can benefit from skipping exon 53 of the dystrophin transcript. The other approved PMO developed by Sarepta is casimersen (AMONDYS45) which is indicated for the treatment of DMD in patients amendable by exon 45 skipping.
In addition to development of Morpholinos as therapeutics, AVI has conducted six human trials for colorectal and pancreatic cancers using their cancer vaccine AVICINE.
In 2019, Sarepta signed a licensing agreement with Roche for the development, and commercialization outside of USA, for SRP-9001. In June 2023, ELEVIDYS (Delandistrogene moxeparvovec) was approved by the FDA for use in 4-5-year-old boys with mutations in the DMD gene. The FDA granted accelerated approval to ELEVIDYS, which requires that the product be further studied to verify its clinical benefit.
In June 2024, the U.S. Food and Drug Administration expanded approval of delandistrogene moxeparvovec to include individuals with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene who are at least 4 years of age. The FDA granted traditional approval for ambulatory patients and accelerated approval for non-ambulatory patients.
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
| Métrica | Tendencia a 5 años | SRPT | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| P/E (TTM) | -10.9promedio 5A ≈-0.3 | ≈-0.3 | · | · | |
| P/S (TTM) | 0.9promedio 5A ≈7.6 | ≈7.6 | 31.2 | Infravalorado | |
| P/C (MRQ) | 1.2promedio 5A ≈11.7 | ≈11.7 | 4.7 | Infravalorado | |
| Precio / FCF (TTM) | 22.6promedio 5A ≈-21.1 | ≈-21.1 | · | · | |
| Precio / Flujo de Caja (TTM) | 16.7promedio 5A ≈-27.8 | ≈-27.8 | · | · | |
| Precio / Valor Contable Tangible (MRQ) | 1.2promedio 5A ≈11.9 | ≈11.9 | · | · |
La mediana de empresas comparables se calcula sobre una base estandarizada por métrica y puede no coincidir siempre con la base TTM/MRQ que se muestra para esta acción.
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
| Métrica | Tendencia a 5 años | SRPT | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Margen Operativo (TTM) | -7.3%promedio 5A ≈-33.0% | ≈-33.0% | -701.6% | De primer nivel | |
| Margen EBITDA (TTM) | -5.0%promedio 5A ≈-29.5% | ≈-29.5% | -701.6% | De primer nivel | |
| Margen antes de impuestos (TTM) | -6.6%promedio 5A ≈-38.7% | ≈-38.7% | -713.3% | De primer nivel | |
| Margen de Beneficio Neto (TTM) | -6.9%promedio 5A ≈-39.6% | ≈-39.6% | -660.8% | De primer nivel | |
| ROA (TTM) | -4.0%promedio 5A ≈-13.2% | ≈-13.2% | -36.5% | De primer nivel | |
| ROE (TTM) | -9.5%promedio 5A ≈-67.7% | ≈-67.7% | -59.5% | En línea | |
| ROIC | -62.3%promedio 5A ≈-53.9% | ≈-53.9% | -63.3% | De primer nivel |
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
| Métrica | Tendencia a 5 años | SRPT | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Ratio corriente (MRQ) | 4.4promedio 5A ≈4.1 | ≈4.1 | 7.2 | Baja liquidez | |
| Ratio Rápido (MRQ) | 2.3promedio 5A ≈3.1 | ≈3.1 | 4.9 | Baja liquidez | |
| Interest Coverage (Cobertura de Intereses) | 18.3promedio 5A ≈-4.6 | ≈-4.6 | -76.8 | Liquidez sólida |
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
| Métrica | Tendencia a 5 años | SRPT | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Revenue YoY (Ingresos interanuales) | 15.6%promedio 5A ≈32.9% | ≈32.9% | · | · | |
| Revenue CAGR 3Y (Ingresos CAGR 3A) | 33.1%promedio 5A ≈34.8% | ≈34.8% | · | · | |
| Revenue CAGR 5Y (Ingresos CAGR 5A) | 32.4% | · | · | · |
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
| Métrica | Tendencia a 5 años | SRPT | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Asset Turnover (Rotación de Activos) | 0.6promedio 5A ≈0.4 | ≈0.4 | 0.1 | De primer nivel | |
| Inventory Turnover (Rotación de Inventario) | 0.0 | · | · | · | |
| Receivables Turnover (Rotación de Cuentas por Cobrar) | 4.4promedio 5A ≈4.6 | ≈4.6 | 7.5 | Débil | |
| Revenue / Employee (Ingresos / Empleado) | ≈$2.6M | · | · | · |
valor · ≈ promedio 5A · mediana sectorial · veredicto relativo a la mediana
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
| Período | Informe | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|---|
| 30 de junio de 2026 | Ago 4, 2026 | $-0.05 | $0.26 | -119.0% |
| 31 de marzo de 2026 | $2.88 | $1.01 | 184.7% | |
| 31 de diciembre de 2025 | $-3.93 | $-1.26 | -213.0% | |
| 30 de septiembre de 2025 | $-0.01 | $-0.83 | 98.8% | |
| 30 de junio de 2025 | $1.89 | $0.77 | 146.8% | |
| 31 de marzo de 2025 | $-4.60 | $-0.97 | -376.2% |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.20B | $1.90B | $1.24B | $933M | $702M | $540M | $381M | $301M | $155M | $5M | $1M | $10M | |
| Cost of Revenue | $26M | · | · | · | · | · | · | · | · | $130.0K | · | · | |
| R&D Expense | · | · | · | · | · | · | · | $402M | $167M | $188M | $146M | $94M | |
| SG&A Expense | $492M | $558M | $482M | $451M | $283M | $318M | $285M | $208M | $123M | $84M | $75M | $49M | |
| Operating Expenses | $2.90B | $1.68B | $1.51B | $1.47B | $1.16B | $1.10B | $1.09B | $645M | $326M | $272M | $221M | $144M | |
| Operating Income | $-700M | $218M | $-268M | $-536M | $-460M | $-564M | $-706M | $-344M | $-172M | $-267M | $-220M | $-134M | |
| Interest Expense | $-38M | $-18M | $-22M | $-53M | $64M | $60M | $31M | $34M | $6M | $2M | $1M | · | |
| Interest Income | $31M | $31M | $36M | $16M | $354.0K | $3M | $7M | $7M | $2M | $507.0K | $890.0K | · | |
| Other Non-op | $-19M | $43M | $33M | $-28M | $-61M | $11M | $-236.0K | $-656.0K | $601.0K | $930.0K | $154.0K | $779.0K | |
| Pretax Income | $-702M | $261M | $-520M | $-690M | $-419M | $-553M | $-714M | $-363M | $-49M | $-267M | $-220M | · | |
| Income Tax | $11M | $26M | $16M | $14M | $-168.0K | $1M | $1M | $-692.0K | $2M | · | · | · | |
| Net Income | $-713M | $235M | $-536M | $-703M | $-419M | $-554M | $-715M | $-362M | $-51M | $-267M | $-220M | $-136M | |
| EPS (Basic) | $-7.13 | $2.47 | $-5.80 | $-8.03 | $-5.15 | $-7.11 | · | · | · | · | · | · | |
| EPS (Diluted) | $-7.13 | $2.34 | $-5.80 | $-8.03 | $-5.15 | $-7.11 | · | · | · | · | · | · | |
| Shares (Basic) | 100,120,000 | 95,075,000 | 92,398,000 | 87,559,000 | 81,262,000 | 77,956,000 | 73,615,000 | 66,250,000 | 58,818,000 | 48,697,000 | 42,290,000 | 40,026,000 | |
| Shares (Diluted) | 100,120,000 | 107,875,000 | 92,398,000 | 87,559,000 | 81,262,000 | 77,956,000 | 73,615,000 | 66,250,000 | 58,818,000 | · | · | · | |
| EBITDA | $-655M | $256M | $-223M | $-494M | $-422M | $-537M | $-675M | $-331M | $-164M | $-261M | · | $-130M |
Balance general
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $801M | $1.10B | $428M | $967M | $2.12B | $1.50B | $835M | $371M | $600M | $122M | $80M | $74M | |
| Short-term Investments | $138M | $252M | $1.25B | $1.02B | $0 | $436M | $290M | $803M | $479M | $195M | $112M | $137M | |
| Receivables | $398M | $602M | $400M | $215M | $153M | $101M | $91M | $49M | $29M | $5M | $4M | $2M | |
| Inventory | $915M | $750M | $323M | $204M | $186M | $232M | $171M | $125M | $84M | $13M | · | · | |
| Prepaid Expense | · | · | · | · | · | · | · | · | · | $1M | $3M | $3M | |
| Other Current Assets | $172M | $90M | $78M | $150M | $149M | $213M | $82M | $78M | $37M | $27M | $17M | $35M | |
| Current Assets | $2.54B | $3.07B | $2.58B | $2.56B | $2.60B | $2.49B | $1.47B | $1.43B | $1.23B | $373M | $225M | $248M | |
| PP&E (Net) | $345M | $340M | $227M | $180M | $191M | $190M | $130M | $97M | $43M | $38M | $37M | $39M | |
| PP&E (Gross) | $626M | $574M | $418M | $329M | $304M | $266M | $181M | $125M | $61M | $68M | $62M | $58M | |
| Accum. Depreciation | $280M | $234M | $191M | $149M | $113M | $76M | $51M | $28M | $18M | $30M | $25M | $20M | |
| Intangibles | $29M | $27M | $30M | $8M | $14M | $14M | $12M | $12M | $14M | $8M | $7M | $6M | |
| Other Non-current Assets | $156M | $80M | $137M | $163M | $293M | $204M | $174M | $107M | $22M | $4M | $4M | $2M | |
| Total Assets | $3.35B | $3.96B | $3.26B | $3.13B | $3.15B | $2.98B | $1.82B | $1.64B | $1.31B | $424M | $274M | $295M | |
| Accounts Payable | $281M | $214M | $165M | $96M | $77M | $111M | $68M | $34M | $8M | $30M | $20M | $12M | |
| Accrued Liabilities | $360M | $374M | $315M | $419M | $272M | $194M | $186M | $134M | $69M | $31M | $29M | $17M | |
| Short-term Debt | · | · | · | · | · | · | · | · | · | · | $2M | $2M | |
| Current Liabilities | $1.10B | $732M | $654M | $620M | $453M | $416M | $265M | $174M | $88M | $75M | $62M | $37M | |
| Capital Leases | $199M | $192M | $141M | $58M | $42M | $80M | $48M | · | · | · | · | · | |
| Other Non-current Liabilities | $2M | $2M | $3M | $42.0K | $11M | $20M | $5M | $16M | $6M | $6M | $6M | $7M | |
| Total Liabilities | $2.21B | $2.44B | $2.41B | $2.74B | $2.22B | $2.22B | $1.00B | $610M | $519M | $87M | $83M | $47M | |
| Long-term Debt | $829M | $1.14B | $1.24B | $1.54B | $564M | · | · | $421M | $431M | $18M | $27M | $7M | |
| Total Debt | · | $0 | $105M | · | · | · | · | · | · | · | · | $4M | |
| Common Stock | $11.0K | $10.0K | $9.0K | $9.0K | $9.0K | $8.0K | $8.0K | $7.0K | $6.0K | $5.0K | $5.0K | $4.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | · | · | $927M | |
| Retained Earnings | $-4.88B | $-4.21B | $-4.45B | $-3.91B | $-3.21B | $-2.85B | $-2.29B | $-1.58B | $-1.22B | $-1.17B | $-899M | $-679M | |
| Treasury Stock | $25M | $0 | · | · | · | · | · | · | · | · | · | · | |
| AOCI | $272.0K | $-218.0K | $918.0K | $-2M | $-20.0K | $3.0K | $50.0K | $-99.0K | $-379.0K | $-120.0K | $-111.0K | $-95.0K | |
| Stockholders' Equity | $1.14B | $1.53B | $859M | $385M | $928M | $762M | $818M | $1.03B | $789M | $337M | $190M | $248M | |
| Liabilities + Equity | $3.35B | $3.96B | $3.26B | $3.13B | $3.15B | $2.98B | $1.82B | $1.64B | $1.31B | $424M | $274M | $295M | |
| Shares Outstanding | 104,964,220 | 96,900,496 | 93,731,831 | 87,950,117 | 87,126,974 | 79,374,247 | 75,184,863 | 71,071,887 | 64,791,670 | 54,759,234 | 45,629,529 | 41,311,512 |
Flujo de Efectivo
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $45M | $38M | $44M | $42M | $38M | $27M | $24M | $12M | $8M | $6M | $5M | $4M | |
| Stock-based Comp | $123M | $184M | $183M | $233M | $114M | $108M | $79M | $50M | $30M | $30M | $32M | $20M | |
| Deferred Tax | $-363.0K | $-249.0K | $-165.0K | $-612.0K | $-309.0K | $-245.0K | $-376.0K | $-240.0K | · | · | · | · | |
| Amort. of Intangibles | $3M | $2M | $2M | $714.0K | $706.0K | $662.0K | $849.0K | $865.0K | $1M | $29.0K | · | · | |
| Restructuring | $42M | $0 | $0 | · | · | · | · | · | $3M | $4M | · | $14.0K | |
| Other Non-cash | $340M | $-663M | $-192M | $104M | $-176M | $527M | $150M | $-89M | $-220M | $-14M | · | $-17M | |
| Operating Cash Flow | $-205M | $-206M | $-501M | $-325M | $-443M | $107M | $-456M | $-389M | $-232M | $-246M | $-149M | $-129M | |
| CapEx | $102M | $137M | $76M | $31M | $38M | $82M | $60M | $61M | $12M | $5M | $3M | $25M | |
| Investing Cash Flow | $70M | $756M | $-166M | $-1.05B | $495M | $-122M | $287M | $-370M | $-179M | $-90M | · | · | |
| Debt Issued | · | · | · | $0 | $0 | $291M | $246M | · | $30M | · | $20M | · | |
| Net Debt Issued | · | · | · | $0 | · | $291M | · | · | $30M | · | · | $-94.0K | |
| Stock Issued | $20M | $0 | $0 | $0 | $0 | $312M | · | $513M | $354M | $365M | $120M | $95M | |
| Stock Repurchased | $25M | $0 | $0 | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $-5M | · | · | $0 | · | $312M | $365M | $513M | $354M | $365M | · | · | |
| Financing Cash Flow | $-168M | $125M | $125M | $233M | $562M | $682M | $643M | $530M | $888M | $378M | · | · | |
| Net Change in Cash | $-304M | $675M | $-542M | $-1.14B | $614M | $668M | $473M | $-229M | $477M | $42M | $7M | $-183M | |
| Taxes Paid | $38M | $23M | $15M | $2M | $583.0K | $3M | $933.0K | $2M | $5M | · | · | · | |
| Free Cash Flow | $-307M | $-343M | $-577M | $-356M | $-482M | $25M | $-516M | $-450M | $-244M | $-251M | · | $-154M | |
| Levered FCF | $-269M | $-326M | $-600M | $-410M | $-545M | $-35M | $-547M | $-483M | $-250M | · | · | · |
Rentabilidad
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -31.8% | 11.5% | -21.5% | -57.5% | -65.5% | -104.5% | -185.3% | -114.1% | -111.0% | -4920.3% | · | · | |
| Net Margin | -32.5% | 12.4% | -43.1% | -75.4% | -59.7% | -102.6% | -187.8% | -120.2% | -32.8% | -4930.2% | · | · | |
| Pretax Margin | -31.9% | 13.7% | -41.8% | -74.0% | -59.7% | -102.4% | -187.5% | -120.4% | -31.5% | · | · | · | |
| EBITDA Margin | -29.8% | 13.5% | -18.0% | -53.0% | -60.1% | -99.5% | -177.2% | -110.1% | -105.8% | -4816.8% | · | · | |
| ROA | -19.5% | 6.5% | -16.8% | -22.4% | -13.7% | -23.1% | -41.3% | -24.5% | -5.9% | -76.6% | · | -46.3% | |
| ROE | -57.1% | 17.1% | -66.0% | -172.5% | -59.9% | -67.0% | -78.9% | -43.3% | -9.0% | -101.4% | · | -54.9% | |
| ROIC | -62.3% | 12.9% | -28.6% | -142.0% | -49.5% | -74.2% | -86.4% | -33.2% | -22.7% | · | · | · |
Liquidez y Solvencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 4.2 | 3.9 | 4.1 | 5.8 | 6.0 | 5.5 | 8.2 | 13.9 | 5.0 | · | 6.7 | |
| Quick Ratio | 1.2 | 2.7 | 3.2 | 3.6 | 5.0 | 4.9 | 4.6 | 7.0 | 12.5 | 4.3 | · | 5.8 | |
| Debt / Equity | · | 0.0 | 0.1 | · | · | · | · | · | · | · | · | 0.0 | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | 0.0 | |
| Interest Coverage | 18.3 | -11.9 | -12.2 | -10.1 | -7.2 | -9.4 | -23.0 | -10.2 | -29.7 | · | · | · |
Eficiencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.6 | 0.5 | 0.4 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.0 | · | · | |
| Inventory Turnover | 0.0 | · | · | · | · | · | · | · | · | 0.0 | · | · | |
| Receivables Turnover | 4.4 | 3.8 | 4.0 | 5.1 | 5.5 | 5.6 | 5.4 | 7.7 | 8.9 | 1.2 | · | · |
Por Acción
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $10.87 | $15.77 | $9.17 | $4.38 | $10.65 | $9.60 | $10.88 | $14.52 | $12.18 | $6.15 | · | $5.99 | |
| Revenue / Share | $21.96 | $17.63 | $13.46 | $10.66 | $8.64 | $6.93 | $5.17 | · | · | · | · | · | |
| Cash Flow / Share | $-2.05 | $-1.91 | $-5.42 | $-3.72 | $-5.45 | $1.38 | $-6.20 | · | · | · | · | · | |
| Cash / Share | $7.63 | $11.38 | $4.57 | $10.99 | $24.28 | $18.93 | $11.11 | $5.22 | $9.26 | $2.24 | · | $1.78 | |
| EPS (TTM) | $-7.13 | $2.34 | $-5.80 | $-8.03 | $-5.15 | $-7.11 | $-3.37 | $-3.37 | $-0.80 | · | $-6.37 | $-6.37 |
Tasas de Crecimiento
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 15.6% | 53.0% | 33.3% | 32.9% | 30.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 33.1% | 39.4% | 32.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 32.4% | · | · | · | · | · | · | · | · | · | · | · |
Valoración (TTM)
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.20B | $1.90B | $1.24B | $933M | $702M | $540M | $381M | $301M | $155M | $5M | $1M | $10M | |
| Net Income TTM | $-713M | $235M | $-536M | $-703M | $-419M | $-554M | $-715M | $-362M | $-51M | $-267M | $-220M | $-136M | |
| Market Cap | $2.26B | $11.78B | $9.04B | $11.40B | $7.85B | $13.53B | $9.70B | $7.76B | $3.61B | $1.50B | · | $598M | |
| Enterprise Value | · | $10.43B | $7.47B | · | · | · | · | · | · | · | · | $391M | |
| P/E | -3.0 | 52.0 | -16.6 | -16.1 | -17.5 | -24.0 | -38.3 | -32.4 | -69.5 | · | -6.1 | -2.3 | |
| P/S | 1.0 | 6.2 | 7.3 | 12.2 | 11.2 | 25.1 | 25.5 | 25.8 | 23.3 | 277.1 | · | 61.3 | |
| P/B | 2.0 | 7.7 | 10.5 | 29.6 | 8.5 | 17.8 | 11.9 | 7.5 | 4.6 | 4.5 | · | 2.4 | |
| P / Tangible Book | 2.0 | 7.9 | 10.9 | 30.2 | 8.6 | 18.1 | · | · | · | · | · | · | |
| P / Cash Flow | -11.0 | -57.3 | -18.0 | -35.0 | -17.7 | 125.9 | -21.3 | -20.0 | -15.5 | -6.1 | · | -4.7 | |
| P / FCF | -7.3 | -34.4 | -15.7 | -32.0 | -16.3 | 535.6 | -18.8 | -17.2 | -14.8 | -6.0 | · | -3.9 | |
| EV / EBITDA | · | 40.8 | -33.4 | · | · | · | · | · | · | · | · | -3.0 | |
| EV / FCF | · | -30.4 | -12.9 | · | · | · | · | · | · | · | · | -2.5 | |
| EV / Revenue | · | 5.5 | 6.0 | · | · | · | · | · | · | · | · | 40.1 | |
| Earnings Yield | -33.1% | 1.9% | -6.0% | -6.2% | -5.7% | -4.2% | -2.6% | -3.1% | -1.4% | · | -16.5% | -44.0% |
Estado de resultados
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $401M | $731M | $443M | $399M | $611M | $745M | $658M | $467M | $363M | $413M | $397M | $332M | $261M | $254M | $258M | $230M | |
| Gross Profit | · | · | $-29M | $219M | $361M | $474M | $506M | $338M | $316M | $309M | · | · | · | · | · | · | |
| SG&A Expense | $108M | $109M | $128M | $92M | $138M | $134M | $164M | $128M | $139M | $127M | $132M | $121M | $119M | $111M | $120M | $105M | |
| Operating Expenses | $388M | $372M | $855M | $503M | $496M | $1.05B | $497M | $445M | $364M | $379M | $372M | $353M | $395M | $392M | $365M | $362M | |
| Operating Income | $13M | $358M | $-412M | $-103M | $116M | $-300M | $162M | $22M | $-701.0K | $35M | $25M | $-21M | $-134M | $-138M | $-107M | $-131M | |
| Interest Expense | $-22M | $-22M | $-46M | $2M | $-5M | $-5M | $-24M | $5M | $5M | $-4M | $-39M | $5M | $5M | $6M | $-100M | $15M | |
| Interest Income | $6M | $6M | $8M | $7M | $5M | $10M | $8M | $8M | $8M | $7M | $9M | $10M | $8M | $9M | $9M | $5M | |
| Other Non-op | $-15M | $-15M | $-22M | $48M | $38M | $-83M | $10M | $12M | $14M | $7M | $16M | $-12M | $17M | $13M | $6M | $378.0K | |
| Pretax Income | $-2M | $343M | $-278M | $-194M | $154M | $-384M | $172M | $34M | $14M | $41M | $40M | $-33M | $-15M | $-513M | $-101M | $-256M | |
| Income Tax | $3M | $12M | $5M | $-14M | $-43M | $64M | $13M | $395.0K | $7M | $5M | $-5M | $8M | $9M | $4M | $8M | $1M | |
| Net Income | $-5M | $331M | $-412M | $-51M | $197M | $-448M | $159M | $34M | $6M | $36M | $46M | $-41M | $-24M | $-517M | $-109M | $-258M | |
| EPS (Basic) | $-0.05 | $3.15 | $-3.93 | $-0.50 | $2.01 | $-4.60 | $1.65 | $0.35 | $0.07 | $0.38 | $0.79 | $-0.46 | $-0.27 | $-5.86 | $-1.24 | $-2.94 | |
| EPS (Diluted) | $-0.05 | $2.88 | $-3.93 | $-0.50 | $1.89 | $-4.60 | $1.50 | $0.34 | $0.07 | $0.37 | $0.79 | $-0.46 | $-0.27 | $-5.86 | $-1.24 | $-2.94 | |
| Shares (Basic) | 105,431,000 | 104,988,000 | · | 100,237,000 | 98,005,000 | 97,362,000 | · | 95,390,000 | 94,618,000 | 93,991,000 | · | 88,889,000 | 88,743,000 | 88,186,000 | · | 87,628,000 | |
| Shares (Diluted) | 105,431,000 | 121,916,000 | · | 100,237,000 | 106,623,000 | 97,362,000 | · | 100,448,000 | 99,144,000 | 99,114,000 | · | 88,889,000 | 88,743,000 | 88,186,000 | · | 87,628,000 | |
| EBITDA | $13M | $369M | · | $-103M | $116M | $-290M | · | $22M | $-701.0K | $44M | · | $-21M | $-134M | $-127M | · | $-131M |
Balance general
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $571M | $464M | $801M | $613M | $511M | $241M | $1.10B | $198M | $384M | $427M | $428M | $542M | $852M | $872M | $967M | $1.04B | |
| Short-term Investments | $217M | $189M | $138M | $238M | $290M | $282M | $252M | $1.00B | $1.08B | $963M | · | $1.19B | $1.01B | $1.01B | · | $1.03B | |
| Receivables | $377M | $395M | $398M | $396M | $527M | $659M | $602M | $435M | $360M | $379M | · | $319M | $237M | $224M | · | $202M | |
| Inventory | $904M | $1.00B | $915M | $1.08B | $994M | $941M | $750M | $566M | $486M | $374M | · | $244M | $227M | $203M | · | $221M | |
| Other Current Assets | $106M | $188M | $172M | $192M | $128M | $105M | $90M | $165M | $75M | $83M | · | $154M | $148M | $180M | · | $131M | |
| Current Assets | $2.22B | $2.31B | $2.54B | $2.72B | $2.66B | $2.43B | $3.07B | $2.69B | $2.68B | $2.46B | · | $2.45B | $2.47B | $2.49B | · | $2.63B | |
| PP&E (Net) | $326M | $336M | $345M | $359M | $372M | $361M | $340M | $306M | $276M | $249M | · | $212M | $189M | $183M | · | $181M | |
| PP&E (Gross) | · | · | $626M | · | · | · | $574M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $280M | · | · | · | $234M | · | · | · | · | · | · | · | · | · | |
| Intangibles | $31M | $31M | $29M | $30M | $31M | $26M | $27M | $28M | $28M | $29M | · | $20M | $18M | $7M | · | $13M | |
| Other Non-current Assets | $146M | $152M | $156M | $73M | $83M | $81M | $80M | $84M | $136M | $176M | · | $137M | $163M | $162M | · | $293M | |
| Total Assets | $3.19B | $3.18B | $3.35B | $3.49B | $3.68B | $3.47B | $3.96B | $3.60B | $3.42B | $3.22B | · | $3.11B | $3.13B | $3.06B | · | $3.16B | |
| Accounts Payable | $51M | $70M | $281M | $94M | $137M | $156M | $214M | $119M | $107M | $92M | · | $88M | $110M | $107M | · | $118M | |
| Accrued Liabilities | $325M | $302M | $360M | $296M | $377M | $392M | $374M | $345M | $350M | $283M | · | $322M | $327M | $346M | · | $369M | |
| Current Liabilities | $503M | $499M | $1.10B | $921M | $920M | $606M | $732M | $699M | $688M | $609M | · | $451M | $499M | $537M | · | $603M | |
| Capital Leases | $198M | $199M | $199M | $215M | $214M | $205M | $192M | $170M | $144M | $140M | · | $135M | $129M | $54M | · | $35M | |
| Other Non-current Liabilities | $2M | $2M | $2M | $1M | $1M | $927.0K | $2M | $1M | $7M | $8M | · | $0 | $38.0K | $38.0K | · | $0 | |
| Total Liabilities | $1.66B | $1.67B | $2.21B | $2.17B | $2.32B | $2.32B | $2.44B | $2.38B | $2.35B | $2.26B | · | $2.35B | $2.38B | $2.35B | · | $2.73B | |
| Long-term Debt | $848M | $838M | $829M | $1.04B | · | · | $1.14B | $1.23B | $1.23B | $1.24B | · | $1.24B | $1.24B | $1.23B | · | $1.54B | |
| Total Debt | · | · | · | · | · | · | · | $92M | $92M | $106M | · | · | · | · | · | · | |
| Common Stock | $11.0K | $11.0K | $11.0K | $11.0K | $10.0K | $10.0K | $10.0K | $10.0K | $10.0K | $9.0K | · | $9.0K | $9.0K | $9.0K | · | $9.0K | |
| Retained Earnings | $-4.55B | $-4.55B | $-4.88B | $-4.64B | $-4.46B | $-4.66B | $-4.21B | $-4.37B | $-4.40B | $-4.41B | · | $-4.49B | $-4.45B | $-4.43B | · | $-3.80B | |
| Treasury Stock | $25M | $25M | $25M | $25M | $25M | · | $0 | · | · | · | · | · | · | · | · | · | |
| AOCI | $-565.0K | $-121.0K | $272.0K | $220.0K | $-51.0K | $34.0K | $-218.0K | $2M | $-1M | $-691.0K | · | $-638.0K | $-1M | $-419.0K | · | $-3M | |
| Stockholders' Equity | $1.53B | $1.51B | $1.14B | $1.32B | $1.36B | $1.14B | $1.53B | $1.22B | $1.08B | $961M | $859M | $764M | $741M | $713M | $385M | $431M | |
| Liabilities + Equity | $3.19B | $3.18B | $3.35B | $3.49B | $3.68B | $3.47B | $3.96B | $3.60B | $3.42B | $3.22B | · | $3.11B | $3.13B | $3.06B | · | $3.16B | |
| Shares Outstanding | 105,623,500 | 105,571,146 | 104,964,220 | 104,768,111 | 97,706,074 | 98,254,898 | 96,900,496 | 95,493,005 | 95,282,600 | 94,490,157 | · | 93,537,355 | 93,273,541 | 93,140,135 | · | 87,766,199 |
Flujo de Efectivo
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $11M | $5M | $18M | $11M | $10M | $10M | $10M | $9M | $9M | $11M | $11M | $11M | $11M | $11M | $11M | |
| Stock-based Comp | $24M | $29M | $30M | $15M | $37M | $41M | $50M | $43M | $50M | $41M | $46M | $48M | $47M | $41M | $51M | $50M | |
| Amort. of Intangibles | $717.0K | $691.0K | $677.0K | $677.0K | $667.0K | $601.0K | $601.0K | $602.0K | $601.0K | $601.0K | $763.0K | $439.0K | $179.0K | $178.0K | $179.0K | $178.0K | |
| Restructuring | · | · | $1M | $41M | · | · | $0 | $0 | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $-574M | · | · | · | $-187M | · | · | · | $-328M | · | · | · | $255M | · | · | |
| Operating Cash Flow | $197M | $-203M | $131M | $-15M | $261M | $-583M | $92M | $-71M | $15M | $-242M | $-55M | $-115M | $-122M | $-209M | $-92M | $-65M | |
| CapEx | $555.0K | $2M | $4M | $23M | $32M | $44M | $38M | $37M | $29M | $32M | $19M | $30M | $18M | $9M | $8M | $8M | |
| Investing Cash Flow | $-93M | $-134M | $96M | $232M | $32M | $-291M | $764M | $-129M | $-99M | $219M | $-64M | $-211M | $97M | $12M | $10M | $19M | |
| Stock Issued | · | · | $0 | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Stock Repurchased | · | · | $0 | $0 | · | · | $0 | $0 | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $0 | $241.0K | $-39M | $-118M | $-24M | $12M | $49M | $14M | $40M | $22M | $2M | $15M | $6M | $102M | $11M | $216M | |
| Net Change in Cash | $104M | $-337M | $188M | $100M | $270M | $-862M | $905M | $-186M | $-44M | $-1M | $-117M | $-310M | $-20M | $-95M | $-72M | $171M | |
| Taxes Paid | $8M | $2M | $16M | $1M | $19M | $835.0K | $11M | $4M | $7M | $909.0K | $6M | $4M | $5M | $535.0K | $339.0K | · | |
| Free Cash Flow | · | $-205M | · | · | · | $-627M | · | · | · | $-275M | · | · | · | $-219M | · | · | |
| Levered FCF | · | $-184M | · | · | · | $-622M | · | · | · | $-278M | · | · | · | $-225M | · | · |
Rentabilidad
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 3.3% | 49.0% | · | -25.9% | 18.9% | -40.3% | · | 4.8% | -0.19% | 8.4% | · | -6.3% | -51.1% | -54.5% | · | -57.0% | |
| Net Margin | -1.2% | 45.3% | · | -45.1% | 32.2% | -60.1% | · | 7.2% | 1.8% | 8.7% | · | -12.3% | -9.2% | -203.8% | · | -111.9% | |
| Pretax Margin | -0.44% | 47.0% | · | -48.6% | 25.1% | -51.5% | · | 7.3% | 3.7% | 10.0% | · | -10.0% | -5.6% | -202.2% | · | -111.4% | |
| EBITDA Margin | 3.3% | 50.5% | · | -25.9% | 18.9% | -39.0% | · | 4.8% | -0.19% | 10.6% | · | -6.3% | -51.1% | -50.0% | · | -57.0% | |
| ROA | -0.14% | 10.0% | · | -5.1% | 5.5% | -13.4% | · | 1.0% | 0.20% | 1.1% | · | -1.3% | -0.78% | -16.9% | · | -8.9% | |
| ROE | -0.34% | 25.0% | · | -14.2% | 16.2% | -42.5% | · | 3.4% | 0.71% | 4.3% | · | -6.9% | -3.3% | -65.8% | · | -57.2% | |
| ROIC | 2.4% | 23.0% | · | -7.3% | 10.9% | -30.7% | · | 1.7% | -0.03% | 2.9% | · | -3.4% | -29.6% | -19.5% | · | -30.6% |
Liquidez y Solvencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.4 | 4.6 | · | 3.0 | 2.9 | 4.0 | · | 3.8 | 3.9 | 4.0 | · | 5.4 | 5.0 | 4.6 | · | 4.4 | |
| Quick Ratio | 2.3 | 2.1 | · | 1.4 | 1.4 | 2.0 | · | 2.3 | 2.6 | 2.9 | · | 4.6 | 4.2 | 3.9 | · | 3.8 | |
| Debt / Equity | · | · | · | · | · | · | · | 0.1 | 0.1 | 0.1 | · | · | · | · | · | · | |
| Interest Coverage | -0.6 | -16.5 | · | -13.7 | 22.1 | 66.7 | · | 4.5 | -0.1 | 8.4 | · | -4.0 | -25.6 | -21.8 | · | -8.9 |
Eficiencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.2 | · | 0.1 | 0.2 | 0.2 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 0.9 | 1.4 | · | 1.0 | 1.4 | 1.4 | · | 1.2 | 1.2 | 1.4 | · | 1.3 | 1.2 | 1.3 | · | 1.3 |
Por Acción
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $14.46 | $14.26 | · | $12.60 | $13.89 | $11.63 | · | $12.79 | $11.30 | $10.17 | · | $8.17 | $7.95 | $7.65 | · | $4.91 | |
| Revenue / Share | $3.81 | $5.99 | · | $3.98 | $5.73 | $7.65 | · | $4.65 | $3.66 | $4.17 | · | $3.73 | $2.94 | $2.87 | · | $2627.80 | |
| Cash Flow / Share | · | $-1.66 | · | · | · | $-5.99 | · | · | · | $-2.44 | · | · | · | $-2.37 | · | · | |
| Cash / Share | $5.41 | $4.40 | · | $5.85 | $5.23 | $2.45 | · | $2.07 | $4.03 | $4.52 | · | $5.79 | $9.13 | $9.36 | · | $11.83 | |
| EPS (TTM) | $-1.60 | $0.34 | · | $-1.71 | $-0.87 | $-2.69 | · | $1.57 | $0.77 | $0.43 | · | $-7.83 | $-10.31 | $-12.69 | · | $-8.22 |
Valoración (TTM)
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.97B | $2.18B | · | $2.41B | $2.48B | $2.23B | · | $1.64B | $1.50B | $1.40B | · | $1.10B | $1.00B | $976M | · | $876M | |
| Net Income TTM | $-137M | $65M | · | $-142M | $-58M | $-248M | · | $122M | $47M | $17M | · | $-691M | $-908M | $-1.12B | · | $-716M | |
| Market Cap | $1.90B | $2.30B | · | $2.02B | $1.67B | $6.27B | · | $11.93B | $15.05B | $12.23B | · | $11.34B | $10.68B | $12.84B | · | $9.70B | |
| Enterprise Value | · | · | · | · | · | · | · | $10.82B | $13.69B | $10.95B | · | · | · | · | · | · | |
| P/E | -11.2 | 64.0 | · | -11.3 | -19.7 | -23.7 | · | 79.5 | 205.2 | 301.1 | · | -15.5 | -11.1 | -10.9 | · | -13.4 | |
| P/S | 1.0 | 1.1 | · | 0.8 | 0.7 | 2.8 | · | 7.3 | 10.0 | 8.7 | · | 10.3 | 10.6 | 13.2 | · | 11.1 | |
| P/B | 1.2 | 1.5 | · | 1.5 | 1.2 | 5.5 | · | 9.8 | 14.0 | 12.7 | · | 14.8 | 14.4 | 18.0 | · | 22.5 | |
| P / Tangible Book | 1.3 | 1.6 | · | 1.6 | 1.3 | 5.6 | · | 10.0 | 14.4 | 13.1 | · | 15.2 | 14.8 | 18.2 | · | 23.2 | |
| P / Cash Flow | · | -11.3 | · | · | · | -10.7 | · | · | · | -50.5 | · | · | · | -61.3 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | 6.6 | 9.1 | 7.8 | · | · | · | · | · | · | |
| Earnings Yield | -8.9% | 1.6% | · | -8.9% | -5.1% | -4.2% | · | 1.3% | 0.49% | 0.33% | · | -6.5% | -9.0% | -9.2% | · | -7.4% |
Período más reciente a la izquierda · valores nulos mostrados como ·
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ingresos | $2.20B | $1.90B | $1.24B | $933M | $702M |
| Margen Operativo % | -31.8% | 11.5% | -21.5% | -57.5% | -65.5% |
| Beneficio neto | $-713M | $235M | $-536M | $-703M | $-419M |
| EPS Diluido | $-7.13 | $2.34 | $-5.80 | $-8.03 | $-5.15 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Deuda / Patrimonio | · | 0.0 | 0.1 | · | · |
| Ratio corriente | 2.3 | 4.2 | 3.9 | 4.1 | 5.8 |
| Ratio Rápido | 1.2 | 2.7 | 3.2 | 3.6 | 5.0 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flujo de caja libre | $-307M | $-343M | $-577M | $-356M | $-482M |
Propietarios institucionales (13F) 366 declarantes · $2.3B total · A fecha de 30 de septiembre de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 50 (-9 vs trimestre anterior) | 60 (+14 vs trimestre anterior) | 101 (-10 vs trimestre anterior) | 125 (-17 vs trimestre anterior) | +3.1M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| BlackRock, Inc. | $341 339 398 | 18 994 958 | 14,85% | Acciones |
| VANGUARD GROUP INC | $254 166 887 | 11 810 729 | 11,06% | Acciones |
| STATE STREET CORP | $160 222 137 | 8 916 090 | 6,97% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $150 543 136 | 8 377 470 | 6,55% | Acciones |
| TWO SIGMA INVESTMENTS, LP | $82 639 268 | 4 598 735 | 3,60% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $82 513 837 | 4 591 755 | 3,59% | Acciones |
| FIRST TRUST ADVISORS LP | $78 456 086 | 4 365 951 | 3,41% | Acciones |
| AQR CAPITAL MANAGEMENT LLC | $76 867 492 | 4 325 689 | 3,35% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $49 818 796 | 2 771 758 | 2,17% | Acciones |
| Erste Asset Management GmbH | $45 513 625 | 2 568 945 | 1,98% | Acciones |
| TWO SIGMA ADVISERS, LP | $44 575 108 | 2 071 334 | 1,94% | Acciones |
| MARSHALL WACE, LLP | $39 642 216 | 2 206 022 | 1,73% | Acciones |
| MORGAN STANLEY | $39 581 468 | 2 202 641 | 1,72% | Acciones |
| Aberdeen Group plc | $39 443 216 | 2 194 948 | 1,72% | Acciones |
| BANK OF AMERICA CORP /DE/ | $36 946 051 | 2 055 985 | 1,61% | Acciones |
| GOLDMAN SACHS GROUP INC | $36 703 734 | 2 042 501 | 1,60% | Acciones |
| UBS Group AG | $29 190 737 | 1 624 415 | 1,27% | Acciones |
| FEDERATED HERMES, INC. | $28 578 248 | 1 590 331 | 1,24% | Acciones |
| LMR Partners LLP | $25 021 428 | 1 392 400 | 1,09% | Opción de venta |
| CITADEL ADVISORS LLC | $23 727 588 | 1 320 400 | 1,03% | Opción de compra |
| NORTHERN TRUST CORP | $21 756 855 | 1 210 732 | 0,95% | Acciones |
| MILLENNIUM MANAGEMENT LLC | $21 446 620 | 1 193 468 | 0,93% | Acciones |
| CITIGROUP INC | $20 755 457 | 1 155 006 | 0,90% | Acciones |
| RENAISSANCE TECHNOLOGIES LLC | $20 151 163 | 1 121 378 | 0,88% | Acciones |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $17 616 368 | 980 321 | 0,77% | Acciones |
| Connor, Clark & Lunn Investment Management Ltd. | $17 493 669 | 973 493 | 0,76% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $16 823 514 | 936 200 | 0,73% | Opción de venta |
| Invesco Ltd. | $16 233 721 | 903 379 | 0,71% | Acciones |
| Legal & General Group Plc | $15 770 961 | 877 627 | 0,69% | Acciones |
| 683 Capital Management, LLC | $14 061 525 | 782 500 | 0,61% | Acciones |
| Bank of New York Mellon Corp | $13 911 725 | 774 164 | 0,61% | Acciones |
| ADAR1 Capital Management, LLC | $13 129 763 | 730 649 | 0,57% | Acciones |
| DIMENSIONAL FUND ADVISORS LP | $12 640 823 | 703 629 | 0,55% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $12 548 685 | 698 313 | 0,55% | Acciones |
| BNP PARIBAS FINANCIAL MARKETS | $12 240 212 | 681 147 | 0,53% | Acciones |
| Jump Financial, LLC | $12 209 627 | 679 445 | 0,53% | Acciones |
| Voleon Capital Management LP | $12 116 183 | 674 245 | 0,53% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $12 059 667 | 671 100 | 0,52% | Opción de compra |
| Qube Research & Technologies Ltd | $10 958 034 | 609 796 | 0,48% | Acciones |
| MACKENZIE FINANCIAL CORP | $10 774 381 | 599 576 | 0,47% | Acciones |
| HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | $10 165 988 | 565 720 | 0,44% | Acciones |
| JPMORGAN CHASE & CO | $9 345 699 | 544 392 | 0,41% | Acciones |
| Point72 Asset Management, L.P. | $9 181 017 | 510 908 | 0,40% | Acciones |
| PRINCIPAL FINANCIAL GROUP INC | $9 175 572 | 510 605 | 0,40% | Acciones |
| Casdin Capital, LLC | $8 445 900 | 470 000 | 0,37% | Acciones |
| Assenagon Asset Management S.A. | $8 165 119 | 454 375 | 0,36% | Acciones |
| PANAGORA ASSET MANAGEMENT INC | $8 120 068 | 451 868 | 0,35% | Acciones |
| Hudson Bay Capital Management LP | $8 086 500 | 450 000 | 0,35% | Acciones |
| Man Group plc | $7 154 647 | 398 144 | 0,31% | Acciones |
| PRUDENTIAL FINANCIAL INC | $7 083 235 | 394 170 | 0,31% | Acciones |
Activistas y propietarios del %+ 5 6 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Richard J. Barry (2) | 5 de mayo de 2015 | · | Presentación inicial | · | SEC |
| George W. Haywood, Cheryl Haywood, Rockall Emerging Markets Master Fund Ltd., Meldrum Asset Management, LLC, Con Egan, Conor O’Driscoll ×2 presentaciones | 22 de abril de 2010 | · | Presentación inicial | · | SEC |
| Eastbourne Capital Management, L.L.C., Richard Jon Barry, Black Bear Offshore Master Fund, L.P., Black Bear Fund I, L.P., Black Bear Fund II, L.L.C. ×4 presentaciones | 8 de marzo de 2010 | · | Presentación inicial | · | SEC |
| Medtronic, Inc., Medtronic International, Ltd. | 14 de febrero de 2005 | · | Presentación inicial | Inversión pasiva | SEC |
| Persona informante no revelada | 8 de enero de 2002 | · | Presentación inicial | Inversión pasiva | SEC |
| Persona informante no revelada | 29 de junio de 2001 | · | Presentación inicial | Inversión pasiva | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Informantes de la empresa 65 insiders · 29 directivos · 18 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Michael Severino | Chief Executive Officer | 28 de julio de 2026 A | 756 104 | 0 | 0 | $0 |
| Douglas S Ingram | Chief Executive Officer | 7 de diciembre de 2025 A | 929 391 | 0 | 0 | $0 |
| David J Boyle II | CEO | 27 de agosto de 2010 P | 70 282 | 0 | 0 | $0 |
| Leslie Hudson | Former CEO | 30 de julio de 2010 M | 384 559 | 0 | 0 | $0 |
| Denis R Burger | Chief Executive Officer | 3 de abril de 2007 A | 151 717 | 0 | 0 | $0 |
| Ryan Ho-Yan Wong | Chief Financial Officer | 4 de septiembre de 2026 F | 121 792 | 0 | 0 | $0 |
| Sandesh Mahatme | EVP, CFO & CBO | 8 de julio de 2020 M | 20 260 | 0 | 0 | $0 |
| Louise Rodino-Klapac | President, R&D and Tech Ops | 4 de septiembre de 2026 F | 203 900 | 0 | 0 | $0 |
| Ian Michael Estepan | Chief Operating Officer | 4 de septiembre de 2026 F | 177 184 | 0 | 1 | $-294 202 |
| Cristin Rothfuss | EVP, General Counsel | 4 de septiembre de 2026 F | 115 519 | 0 | 0 | $0 |
| Bilal Arif | Chief Tech Ops Officer | 5 de agosto de 2025 A | 32 500 | 0 | 0 | $0 |
| Dallan Murray | Chief Customer Officer | 10 de marzo de 2025 A | 38 202 | 0 | 0 | $0 |
| Ryan Edward Brown | EVP, General Counsel | 25 de junio de 2024 M | 17 129 | 0 | 0 | $0 |
| William Ciambrone | EVP | 7 de marzo de 2022 A | 22 099 | 0 | 0 | $0 |
| Joseph Bratica | Principal Financial Officer | 11 de diciembre de 2020 M | 8 140 | 0 | 0 | $0 |
| David T Howton | EVP, General Counsel | 22 de junio de 2020 M | 31 871 | 0 | 0 | $0 |
| Alexander Cumbo | EVP, Chief Commercial Officer | 28 de febrero de 2020 A | 8 567 | 0 | 0 | $0 |
| Shamim Ruff | SVP, Chief Regulatory Affairs | 22 de mayo de 2018 M | 31 936 | 0 | 0 | $0 |
| Guriqbal S. Basi | SVP, Chief Scientific Officer | 5 de marzo de 2018 A | · | 0 | 0 | $0 |
| Arthur M Krieg | SVP, Chief Scientific Officer | 13 de enero de 2014 A | · | 0 | 0 | $0 |
| Michael A Jacobsen | VP of Finance and PAO | 23 de agosto de 2012 A | 7 500 | 0 | 0 | $0 |
| Bracha Ephrat Toshav | Sr VP & General Counsel | 31 de agosto de 2011 A | · | 0 | 0 | $0 |
| Melinda G Mile | Controller and PAO | 31 de agosto de 2011 A | · | 0 | 0 | $0 |
| Peter S Linsley | SVP & Chief Scientific Officer | 16 de mayo de 2011 A | · | 0 | 0 | $0 |
| Graham Johnson | Sr VP Preclinical Dev & Rsrch | 23 de agosto de 2010 A | · | 0 | 0 | $0 |
| Paul Medeiros | SVP Business Development | 23 de agosto de 2010 A | · | 0 | 0 | $0 |
| Stephen B Shrewsbury | SVP/Regulatory Affairs | 23 de agosto de 2010 A | 60 000 | 0 | 0 | $0 |
| Patrick L Iversen | Sr VP of Research & Devlopment | 23 de agosto de 2010 A | 86 303 | 0 | 0 | $0 |
| Dwight D Weller | Sr. VP Chemistry & Mfg. | 23 de agosto de 2010 A | 314 741 | 0 | 0 | $0 |
| Michael Andrew Chambers | Consejero | 4 de junio de 2026 A | 27 535 | 0 | 0 | $0 |
| Stephen Mayo | Consejero | 4 de junio de 2026 A | 18 640 | 0 | 1 | $-123 208 |
| Kathryn Jean Boor | Consejero | 4 de junio de 2026 A | 25 138 | 0 | 0 | $0 |
| Claude Nicaise | Consejero | 4 de junio de 2026 A | 48 407 | 0 | 0 | $0 |
| Richard Barry | Consejero | 4 de junio de 2026 A | 2 983 542 | 0 | 0 | $0 |
| Hans Lennart Rudolf Wigzell | Consejero | 4 de junio de 2026 A | 42 098 | 0 | 0 | $0 |
| Deirdre P Connelly | Consejero | 4 de junio de 2026 A | 22 100 | 0 | 0 | $0 |
| Kathleen M Behrens | Consejero | 4 de junio de 2026 A | 214 357 | 0 | 0 | $0 |
| Mary Ann Gray | Consejero | 7 de marzo de 2022 A | 12 356 | 0 | 0 | $0 |
| John C Martin | Consejero | 3 de marzo de 2021 A | 7 913 | 0 | 0 | $0 |
| Michael W Bonney | Consejero | 28 de febrero de 2020 A | 9 126 | 0 | 0 | $0 |
| Edward M. Kaye MD | Consejero | 3 de agosto de 2017 M | 71 229 | 0 | 0 | $0 |
| Jean-Paul Kress | Consejero | 10 de marzo de 2017 A | 2 000 | 0 | 0 | $0 |
| Ben Gil Price | Consejero | 14 de marzo de 2016 P | 42 830 | 0 | 0 | $0 |
| William Alden Goolsbee | Consejero | 29 de febrero de 2016 A | 8 166 | 0 | 0 | $0 |
| EASTBOURNE CAPITAL MANAGEMENT LLC/CA | Propietario del 10% | 4 de marzo de 2010 S | 5 659 211 | 0 | 0 | $0 |
| MEDTRONIC INC | Propietario del 10% | 25 de mayo de 2004 S | 0 | 0 | 0 | $0 |
| Gilmore Neil O'Neill | · | 3 de marzo de 2021 A | 28 546 | 0 | 0 | $0 |
| Catherine Stehman-Breen | · | 3 de abril de 2017 A | · | 0 | 0 | $0 |
| Jayant Aphale | · | 19 de septiembre de 2016 M | 11 490 | 0 | 0 | $0 |
| Nishan Garabedian Christopher | · | 27 de febrero de 2015 A | 29 552 | 0 | 0 | $0 |
| Anthony R Chase | · | 27 de febrero de 2015 A | 67 194 | 0 | 0 | $0 |
| John Hodgman | · | 27 de febrero de 2015 A | 6 333 | 0 | 0 | $0 |
| Anthony Martignetti | · | 4 de junio de 2013 A | · | 0 | 0 | $0 |
| Ryszard Kole | · | 9 de febrero de 2010 A | 1 862 926 | 0 | 0 | $0 |
| George Weaver Haywood | · | 25 de agosto de 2009 P | 8 213 717 | 0 | 0 | $0 |
| Michael D Casey | · | 19 de mayo de 2009 A | 5 000 | 0 | 0 | $0 |
| FORREST K MICHAEL | · | 19 de mayo de 2009 A | 15 000 | 0 | 0 | $0 |
| Christopher S Henney | · | 31 de marzo de 2009 A | · | 0 | 0 | $0 |
| John W Fara PHD | · | 20 de mayo de 2008 A | · | 0 | 0 | $0 |
| Peter D Ohanley | · | 28 de febrero de 2008 A | · | 0 | 0 | $0 |
| Mark Miles Webber | · | 28 de febrero de 2008 A | · | 0 | 0 | $0 |
| Alan P Timmins | · | 2 de febrero de 2008 J | · | 0 | 0 | $0 |
| James B Hicks | · | 22 de mayo de 2007 A | 6 000 | 0 | 0 | $0 |
| Jack L Bowman | · | 22 de mayo de 2007 A | 5 000 | 0 | 0 | $0 |
| Joseph B Horn | · | 22 de marzo de 2006 A | · | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Propiedad de ETFs Mantenido por 56 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 2,63% | 620 211 SH | 2 de octubre de 2026 | Diario |
| IBRN · iShares Trust | 2,18% | 7 938 SH | 11 de septiembre de 2026 | Diario |
| BBP · ETFis Series Trust I | 1,34% | 88 646 NS | 31 de julio de 2026 | N-PORT |
| PSCH · Invesco Exchange-Traded Fund Trust … | 1,02% | 100 590 SH | 2 de octubre de 2026 | Diario |
| HAPS · Harbor ETF Trust | 0,81% | 92 720 NS | 31 de julio de 2026 | N-PORT |
| XSHQ · Invesco Exchange-Traded Fund Trust … | 0,50% | 82 108 SH | 2 de octubre de 2026 | Diario |
| LABU · Direxion Shares ETF Trust | 0,45% | 151 157 NS | 31 de julio de 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,44% | 5 675 SH | 2 de octubre de 2026 | Diario |
| IBB · iShares Trust | 0,15% | 772 730 SH | 11 de septiembre de 2026 | Diario |
| SMDX · Tidal Trust III | 0,15% | 13 054 NS | 31 de julio de 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0,14% | 64 607 SH | 19 de agosto de 2026 | Diario |
| VIOG · VANGUARD ADMIRAL FUNDS | 0,13% | 76 657 SH | 19 de agosto de 2026 | Diario |
| ESSC · Strategy Shares | 0,13% | 3 094 NS | 31 de julio de 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0,13% | 2 065 NS | 31 de julio de 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,12% | 7 460 SH | 2 de octubre de 2026 | Diario |
| QVMS · Invesco Exchange-Traded Fund Trust … | 0,11% | 15 261 SH | 2 de octubre de 2026 | Diario |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,11% | 84 228 SH | 19 de agosto de 2026 | Diario |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,11% | 95 830 NS | 31 de julio de 2026 | N-PORT |
| RWJ · Invesco Exchange-Traded Fund Trust … | 0,10% | 113 747 SH | 2 de octubre de 2026 | Diario |
| VIOO · VANGUARD ADMIRAL FUNDS | 0,10% | 369 221 SH | 19 de agosto de 2026 | Diario |
| VIOV · VANGUARD ADMIRAL FUNDS | 0,08% | 87 370 SH | 19 de agosto de 2026 | Diario |
| IWM · iShares Trust | 0,07% | 2 658 934 SH | 11 de septiembre de 2026 | Diario |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,06% | 598 819 SH | 19 de agosto de 2026 | Diario |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,06% | 27 534 NS | 31 de julio de 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,05% | 1 332 977 SH | 19 de agosto de 2026 | Diario |
| RSSL · Global X Funds | 0,05% | 49 826 NS | 31 de julio de 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,03% | 299 980 SH | 19 de agosto de 2026 | Diario |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,02% | 8 682 NS | 31 de julio de 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,02% | 46 891 NS | 31 de julio de 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,02% | 1 210 549 SH | 19 de agosto de 2026 | Diario |
| VB · VANGUARD INDEX FUNDS | 0,02% | 2 292 990 SH | 19 de agosto de 2026 | Diario |
| WSML · iShares Trust | 0,02% | 6 093 SH | 11 de septiembre de 2026 | Diario |
| DXUV · Dimensional ETF Trust | 0,02% | 6 769 NS | 31 de julio de 2026 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0,01% | 68 063 SH | 2 de octubre de 2026 | Diario |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,01% | 7 772 SH | 19 de agosto de 2026 | Diario |
| IWO · iShares Trust | 0,01% | 67 657 SH | 11 de septiembre de 2026 | Diario |
| TILT · FlexShares Trust | 0,01% | 13 904 NS | 31 de julio de 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,01% | 83 934 NS | 31 de julio de 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0,01% | 11 994 NS | 31 de julio de 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 8 729 NS | 31 de julio de 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 141 450 SH | 11 de septiembre de 2026 | Diario |
| DFUS · Dimensional ETF Trust | 0,00% | 37 436 NS | 31 de julio de 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 25 570 SH | 11 de septiembre de 2026 | Diario |
| DFAU · Dimensional ETF Trust | 0,00% | 22 144 NS | 31 de julio de 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 65 871 NS | 31 de julio de 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 3 187 072 SH | 19 de agosto de 2026 | Diario |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 80 332 SH | 19 de agosto de 2026 | Diario |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 8 458 SH | 19 de agosto de 2026 | Diario |
| ESGV · VANGUARD WORLD FUND | 0,00% | 23 052 SH | 19 de agosto de 2026 | Diario |
| IJR · iShares Trust | · | 6 444 975 SH | 10 de septiembre de 2026 | Diario |
| IJT · iShares Trust | · | 613 122 SH | 9 de septiembre de 2026 | Diario |
| IJS · iShares Trust | · | 369 121 SH | 8 de septiembre de 2026 | Diario |
| IWN · iShares Trust | · | 910 181 SH | 11 de septiembre de 2026 | Diario |
| XJR · iShares Trust | · | 14 552 SH | 31 de agosto de 2026 | Diario |
| ISCB · iShares Trust | · | 4 621 SH | 11 de septiembre de 2026 | Diario |
| ISCV · iShares Trust | · | 22 361 SH | 11 de septiembre de 2026 | Diario |
SRPT Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
Precio objetivo a 12 meses
22 analistas · 2026-10-03Objetivo medio $21.73 +24,2%
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
Base del ejercicio fiscal, precios al cierre del último ejercicio fiscal de cada empresa.
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| SRPT | $2.26B | -3.0 | 15.6% | -32.5% | -57.1% | · |
| BHVN | $1.50B | -1.6 | · | · | -310.8% | · |
| PVLA | $1.30B | -28.2 | 65.3% | -1610.6% | -110.1% | · |
| ABSI | $529M | -4.2 | -38.2% | -4113.7% | -63.5% | · |
| AGIO | $1.59B | -3.8 | 48.0% | -764.0% | -32.2% | · |
| VIR | $841M | -1.9 | -7.6% | -638.9% | -51.1% | · |
| GENB | · | · | · | · | · | · |
| NVAX | $1.09B | 2.6 | 64.7% | 39.2% | -977.1% | · |
| NTLA | $1.05B | -2.4 | 16.9% | -609.8% | -59.5% | · |
| STOK | $1.87B | -264.5 | 404.5% | -3.7% | -2.0% | · |
Últimas noticias Noticias recientes que mencionan a esta empresa
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
Seleccione las métricas que le importan: haga clic en el + junto a cualquier fila en Fundamentales completos arriba.
Tu selección se guarda y te sigue en todos los tickers.